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“Talk to yourself at least once in a Day.. Otherwise you 
may miss a meeting with an EXCELLENT person in this 
World…” 
Swami Vivekananda

ABSTRACT 
Dendritic cells (DCs) are unique antigen presenting cells that bridge innate and 
adaptive immunity. DCs sense invading microbes, sample antigen and migrate to the draining 
lymph node (DLN) where they prime T cells to the microbe. In spite of many advances in DC 
biology, little is known about what happens in the DLN after inoculation of Mycobacterium 
bovis Bacille Calmette-Guérin (BCG) in the skin. A BCG footpad infection model was used 
in this thesis to investigate the above caveat. Some of the important points addressed are the 
subsets of DCs that migrate from skin to DLN in response to BCG and the factors that 
regulate this migration. We developed 5- and 6-carboxyfluorescein diacetate succinimidyl 
ester (CFSE)- based assay to track cell migration from the footpad to the DLN. We found 
EpCAMlow CD11bhigh DCs to be the main migratory skin DC subset to relocate to the DLN in 
response to BCG in this model. Migratory DCs were found to home to the T-cell area of the 
LN, and to co-localize with BCG. 
DC and BCG entry into DLN is dependent on IL-1R and MyD88-dependent 
signaling. The requirement for MyD88 in this process is both DC-intrinsic and -extrinsic. The 
contribution of the IL-1R ligands IL-1α and IL-1β were found to be redundant for the entry of 
skin DCs and BCG into the DLN. In addition, DC relocation to DLN is dependent on the 
BCG inoculation dose, but not on viability of the injected bacilli. Antigen-specific CD4+ T 
cells expansion to BCG is, however, superior when heat-killed BCG is used. Furthermore, the 
nematode Heligmosomoides polygyrus (bakeri), which establishes a chronic but localized gut 
infection, was found to reduce BCG-triggered skin DC migration and to mute BCG-specific 
CD4+ T cell responses in the DLN. 
In summary, using a mouse model of BCG infection, this thesis highlights the 
discovery of a migratory skin DC sub-population that relocates in an MyD88-dependent 
manner to the DLN in response to BCG and reports on a series of factors that impact on 
BCG-triggered skin DC migration in this model, including cytokines, BCG viability, BCG 
dose, and co-infection with a gut nematode.  
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1. INTRODUCTION 
 
The immune system mediates resistance to infection and tolerance to self. It can be 
broadly divided into an innate and an adaptive arm. Cells of innate immunity include 
phagocytes such as macrophages, dendritic cells (DCs) and neutrophils, and innate 
lymphoid cells such as natural killer cells. Innate immune cells use germline-encoded 
receptors to recognize invading microbes. T cells and B cells belong to the adaptive 
immune system. They have somatically rearranged receptors with randomly-generated 
specificities. DCs are innate immune cell that have a key role in orchestrating the adaptive 
immune responses (1). In tissue DC are exposed to antigen which may allow them to 
undergo maturation and consequently migrate to draining lymph node (DLN), where they 
can activate or “prime” naïve T cells. Thus, DCs play a central role in initiating adaptive 
immune responses needed to effectively control microbial growth and to create memory to 
re-infection. Highlighted below are characteristics of DCs relevance to their migratory and 
T cell priming capacity, which both are highly relevant to understand the initiation of 
immune responses to mycobacteria 
 
1.1. DCs 
 
DCs are a heterogeneous population of phagocytes that reside in tissue as well as in 
secondary lymphoid organs. They are potent antigen presenting cells (APCs), which are 
involved in promoting both adaptive immune responses to pathogens and in maintaining 
tolerance to self-antigens (2). Since their discovery by Ralph Steinman in 1973 (3), extensive 
research has been done on the biology of DCs, characterizing among other things their 
contribution to immunity, tolerance, vaccination and immunotherapy. These advances have 
lead to the identification of several distinct DC subsets by the presence of unique surface and 
intracellular phenotypic markers based on immunological function or anatomic distribution 
(4). 
 
1.2. Skin and lymph node DC network 
 
DCs express MHC-II and the CD11c integrin (5). Co-expression of MHC-II and 
CD11c together with additional markers are used to classify DCs further into distinct subsets. 
Classification of DCs into distinct subsets with different abilities to process and present 
antigen can be based on their anatomical location, ability to migrate to DLN and commitment 
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to initiate distinct T-cell effector responses (6). The study of non-lymphoid tissue DCs 
involves the surfaces that are in contact with the environment, which includes skin and 
mucosal surfaces. The skin has received a lot of focus since it houses a large population of 
DCs and is a highly accessible surface for experimentation in laboratory animals. Skin acts as 
a barrier for physical stress, environmental antigen/pathogens, and chemical agents. Hence, 
immune cells in skin have to be prepared to distinguish between self and non-self, to induce 
protective immunity or tolerance (7). DCs in the skin serve as sentinels. They play a crucial 
role in guarding the host against pathogens from the environment. Langerhans cells (LCs) are 
typical DC residents of skin. LCs resides in the epidermis and can move to the DLN. The 
chemokine receptor, CCR7 is needed for the migration of LCs from the epidermis to DLN 
(8). LCs are identified by surface expression of Langerin (CD207), CD11b, EpCAM (CD326) 
and Sirpα (7). LCs were previously believed to be the principal skin DC that sense, 
phagocytize and transport microbial antigen to DLN for the initiation of immune responses 
(9). However, studies from epidermal infection with Herpes simplex virus type 1 (HSV-1) 
suggest that LCs are not an important APC for priming T- cell responses (10, 11). Studies 
show instead that LCs are precommitted to immune tolerance induction (12). Whether LCs 
are tolerogenic or immunogenic may depend on type of antigens, cytokine profiles in the 
environment and the maturation status of the cell itself (2). 
 
Dermal DCs (DDCs) are another population of DCs in the skin. They are found in the 
dermis (as suggested by their name) and like LCs, migrate to DLN via afferent lymphatics 
(13). DDC sub-populations can be classified on the basis of three surface markers, namely 
CD103, CD207 and CD11b. Four subsets of DDCs can be identified with these markers: 
CD103+ CD207+, CD103- CD207+, CD207- CD11b+, and CD207- CD11b DDCs. These 
markers also identify LCs in the DLN, which are migratory CD11blow to high and CD207inter to 
high (mLCs) (14, 15). DDC migration to cutaneous lymph nodes (LNs) is CCR7-dependent 
(15, 16). In the LN, DDCs efficiently present antigens (Ags) to CD4+ T cells, which lead to 
the activation and expansion of the T cells (17-19). During HSV-1 infection, CD103+ DDCs 
play a unique role in presenting viral Ags to naïve CD8+ T cells (17). CD103- DDCs also 
migrate to DLN in response to chemical stress or mechanical injury (20).  
 
LN-resident DCs are classified into two main subsets based on surface expression of 
CD8 and CD11b; namely CD8+ CD11b- and CD8- CD11b+ DCs (5). LN-resident DCs are 
positioned close to LN conduits in the paracortex of the LN, facilitating them to present 
soluble antigen from lymph to T cells (21). Also, studies suggest that LN-resident DCs 
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control the entry of lymphocytes by modulating the maturation state of high endothelial 
venules (22). CD8+ DCs can cross-present antigens acquired from skin DCs that have 
migrated to DLN (10). CD8+ DCs and CD103+ DDCs share in common the transcription 
factors Batf3 and IRF8, which are important in controlling their development (23, 24). 
 
1.3. DC maturation 
 
DCs play an important function in patrolling body surfaces, from where they sample 
Ags and then traffic to DLN to initiate adaptive immune responses (4). Mechanisms by which 
DCs sample Ags include phagocytosis (25), endocytosis and macropinocytosis (26). 
Immature DCs are highly phagocytic compared to its mature DCs (25). Immature DCs are 
specialized at directly recognizing pathogen- or danger-associated molecular patterns 
(PAMPs or DAMPs) by their germline-encoded pattern recognition receptors (PRRs). The 
initial sensing of infection is mediated by such PRRs, which include Toll-like receptors 
(TLRs), C-type lectin receptors, retinoic acid-inducible gene I-like receptor (RIG-I-like 
receptors) and nucleotide-binding oligomerization domain-like receptors (NOD-like 
receptors) (27). Among the above-mentioned PRRs, TLRs are the best characterized. In 
mouse there are 11 TLR members that are positioned either on the cell surface (TLRs 1,2,4,5 
and 6) or on endosomal membranes (TLRs 3,7,8 and 9) (28, 29). TLRs work as homo- or 
heterodimers, to recognize very divergent PAMPs including components from bacteria, 
fungi, viruses and protozoans. TLR signaling leads to the recruitment of different intracellular 
adaptor molecules like myeloid differentiation primary response 88 (MyD88), Toll-
interleukin 1 receptor domain containing adaptor protein (TIRAP), Toll-interleukin 1 receptor 
domain containing adaptor protein interferon-β (TRIF) and TRIF-related adaptor molecule 
(TRAM) (27, 30). MyD88 is used by all the 11 identified TLRs except for TLR3. MyD88 is 
important for DC activation and prominent in initiating Th1 response to Mycobacterium (31, 
32). TLR activation initiates innate immune responses and also regulates adaptive immune 
responses to pathogens by activation of NF-κB and distinct IRF3 pathways that upregulate 
pro-inflammatory cytokines and type I IFNs (27). IL-1R signaling also uses MyD88 for 
switching on the upregulation of inflammatory cytokines (33), which can amplify the 
adaptive response by attracting and activating innate immune cells like monocytes and 
neutrophils to the target tissue (34).  
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Activation of DCs is associated with varied expression levels of integrins, MHC-II 
and co-stimulatory molecules like CD80, CD86, and CD40 (35). Antigen processing 
machineries vary between different DC subsets. CD8+ DCs are efficient in processing antigen 
for presentation on MHC-I, whereas CD8- DCs excel at presenting antigen on MHC-II (36, 
37). Depending on the type of activation stimulus, the functionality of the DC can be either 
inflammatory or anti-inflammatory. 
 
Interestingly, PRRs expressed on DCs sense several PAMPs from mycobacteria, 
such as the cell wall components lipomannan (LM), lipoarabinomannan (LAM) and its 
mannosylated form (ManLAM) and ESAT-6 (secreted protein) (38). The PRRs that are 
involved in the above recognition include TLR-2 (39), TLR-4 (40), Mannose receptor, DC-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) (41), Dectin-1 
(42, 43) and Dectin-2 (44). (Another C-type lectin is Mincle. NOD-2 also recognizes 
mycobacteria). Mycobacterial PAMPs that make their way into the cytosol, can activate 
intracellular PRRs, like TLR-9. TLR9 binds to CpG motifs, non-methylated DNA sequences 
(31). Triggering of PRRs leads to the activation of NF-κB and culminates with the 
transcription of several genes important for inflammation (30). All these sequential events 
trigger DC maturation that can be detected by i) upregulation of co-stimulatory molecules, ii) 
increase in antigen presentation machinery and iii) pro-inflammatory cytokine production like 
interleukin-1β (IL-1β), interleukin-12 (IL-12) and tumor necrosis factor alpha (TNF-α) (45). 
Further, IL-12 and TNF-α secretion will induce IFN-γ production from natural killer and T 
cells (46). IFN-γ also stimulates DCs to increase their phagocytic activity. An activated DC 
that has migrated to the LN is now capable of activating antigen-specific T cells that can help 
control infection (47). 
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Figure 1. Phenotypic changes that accompany DC maturation. Modified from (48, 49).  
 
1.4. DC trafficking molecules 
 
Trafficking of mature DCs will upregulate chemoattractant-dependent receptors and 
adhesion molecules that can respond to a broad variety of ligands (50, 51). The migration of 
DCs to both lymphoid and non-lymphoid tissue depends on the relative expression of 
chemokine receptors on DCs and the availability of chemokine ligands in the tissue. 
 
1.4.1. Migration of DCs to non-lymphoid tissue 
 
Immature DCs migrate to non-lymphoid tissue by utilizing a variety of chemokine 
receptor pathways, like CCR2-CCL2 (52, 53), CCR6-CCL20 (53) and CCR5-CCL5 (54, 55). 
Activated endothelium express E- and P-selectin, which helps in tethering and rolling of 
immature DCs, monocytes and plasmacytoid DCs (56-58). Irradiation studies confirm that 
circulating LC migrates to inflamed skin with the help of CCR2/6. Inflammation also boosts 
expression of the CCR2/6 and corresponding ligands CCL2/7 and CCL20, favoring more LC 
migration to the inflamed skin (53, 59).  
 
1.4.2. Migration of DC to DLNs 
 
In steady state, DCs in tissue continuously relocate via lymphatic vessels to DLN 
(60). This trafficking of DCs from tissue is increased during inflammation and infection. The 
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mobilization of DCs to DLN is a complicated process that involves many steps. Each step is 
discussed below in the context of skin DC migration. 
 
1.4.3. Mobilization from tissue 
 
The skin microenvironment provides signals for the retention of DCs in the skin (61, 
62). It is well established that LCs in the epidermis are anchored with keratinocytes through 
E-cadherin (63, 64). Selective disruption of E-cadherin junction interactions between LCs and 
keratinocytes promotes enhanced LC migration by upregulating CCR7 (65). Similar 
observations are seen when mice that are treated with IL-1β, TNF-α or LPS (66). On the 
other hand, TGF-β treatment upregulates E-cadherin expression on DC precursors and 
inhibits their maturation (67) and CCR7 expression (68). After detachment from skin, DCs 
migrate through the extracellular matrix. DC upregulation of metalloproteinases (MMPs) 
facilitates their migration through this matrix of collagen, fibronectin and laminin. In 
particular skin DCs upregulate MMP-2 and MMP-9 (69).  
 
1.4.4. Traversing the afferent lymphatic endothelium 
 
After making their way through the extracellular matrix, skin DCs enter the initial 
dermal lymphatic vessels by traversing through oak leaf-shaped lymphatic endothelial cells 
(70). This step requires upregulation of E-selectin and chemokine ligands. Lymphatic 
endothelial cells stimulated with inflammatory cytokines (TNF-α) upregulate E-selectin, 
chemokines CCL5, CCL20, and CXCL5, and adhesion molecules ICAM-1 and VCAM-1 
(71). Blocking the ability of lymphatic endothelial cells to express adhesion molecules either 
by neutralizing antibodies or by genetic disruption leads to reduced DDC transmigration of 
lymphatics (71) and impaired LC migration to DLN (72). 
 
1.4.5. DC motility within SLOs 
 
DCs exit lymphatic vessels and enter the sub-capsular sinus floor of the LN. This is an 
active process involving CCR7 expression on DC and CCL21 ligand expression on the sub 
capsular sinus wall of the LN (73). Within the LN, DCs also use CCR7 for migration. DCs 
depend on CCL21 gradient and are believed to guide them towards the high endothelium 
venules (HEVs) (74), where expression of CCR7 ligands CCL19 and CCL21 are high. 
 
  7 
DC motility behavior relies on amoeboid movement (75). DC amoeboid movement is 
characterized by actin polymerization events in the leading-end of the cell. This is mediated 
by Rac1, Rac2 (76), the Rho GTPase family member cdc42 (77) and leads to the formation of 
protrusions. In rear-end of the DC, actinomyosin contractions are mediated by Rho-
associated protein kinase (ROCK). In line, disruption of Rac-1 and Rac-2 leads to ablation of 
DC migration from skin to LN (76) and inhibition of ROCK significantly reduces the velocity 
of DCs in the interstitium of the ear skin (78).  
 
To date, CCR7 and its ligands CCL19 and CCL21 is the most well-established 
chemokine pathway for DC migration from skin to DLN. In support of this statement, DC 
migration from tissue to LN is reduced in plt/plt mice, which lack CCL19 and CCl21-ser (74, 
79, 80). Plt/plt mice have small LNs and a reduced number of migratory skin DCs in skin 
DLN. Injection of TNF-α in the skin triggers DC migration to DLN (67) and is associated 
with increased expression of CCL21 by lymphatic endothelial cells. Finally, CCR7-/- mice 
confirm the key role of this receptor on DCs for their migration from skin to DLN (16, 81, 
82). Studies with CCR7-/- and plt/plt mice show the importance of CCR7 and its ligands in the 
migration of skin DCs to DLN. 
 
However, CCR7 is not the only chemokine receptor that regulates DC migration (83). 
Adoptive transfer experiments showed although there is uniformly high expression of CCR7 
on CD8+ DCs, their migration to DLN is reduced when compared with CD8α−/lo DCs which 
express less CCR7 (84). The above finding suggests that other guiding molecules may be 
involved in DC migration, such as lipid mediators (85). Indeed, FITC-painting experiments 
suggest that CXCR4 contributes to both LC and DDC migration to LN in a CCR7-
independent manner (4).  
 
1.5. Methods to track the migration: 
 
The development of DC-tracking assays such as FITC-skin painting, discussed below, 
has helped to uncover the voyage that DCs make from tissue to DLN. Techniques to study 
DC migration include confocal microscopy, which allows the study of DCs and their location 
in the tissue and intravital microscopy that allows the study of DC migration in real-time (58, 
86). Microscopy can be combined with flow cytometry, which allow thorough 
characterization of the migrating DC with different surface markers.  
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DC migration from tissue to LN has been readily studied by applying  fluorochromes 
to the skin surface as a way to label local DCs and then following these labeled DCs by 
different techniques, such as the ones mentioned above. Injecting fluorescent beads in the 
skin is one approach, but by far the most commonly used technique is to “paint” the skin with 
fluorescein isothiocyanate (FITC) mixed with a skin irritant. FITC-labeled LCs and DDCs or 
monocyte-derived DCs can then be quantified in LN by flow cytometry or microscopy (87, 
88) In other studies Carboxyfluorescein succinimidyl ester (CFSE) is given intranasally to 
label airway DCs (89, 90). Also, antigens or proteins can be flurochrome-coupled and used to 
study fluorescent populations that become associated with the antigen (91, 92). A potential 
drawback of the above is to assure the primary location of cell labeling in the tissue. The 
antigen/flourochorme label may leak due to cell death and other populations may take up the 
fluorochrome-labeled antigen and also become labeled (89, 92). Another caveat is that the 
labeling intensity may decrease with time, due to cell metabolism or turnover of the labeled 
proteins in the cells. Finally, reporter mice where DCs are permanently or conditionally 
labeled with fluorescent proteins, such as Kaede transgenic mice (93), have become a popular 
way to track DCs migration in vivo (14, 94). A drawback of this approach is or may be that 
the expression of reporter protein may change as DCs mature. 
 
1.6. Initiation of T-cell response by DCs 
 
DCs in SLOs activate or “prime” naïve T-cells into action. This process requires a 
combination of three unique signals provided to the T cell by the DC. These signals are 
commonly referred to as Signal 1, 2 and 3, and trigger T-cell activation, proliferation and 
differentiation. This is discussed below in the context of CD4+ T cells and summarized as 
part of Figure 2. Signal 1, or antigen presentation, is the presentation of peptide antigen 
anchored onto MHC-II. It leads to triggering of the T-cell receptor (TCR) on the T cell. 
Signal 2 or co-stimulation, is mediated by expression of co-stimulatory molecules CD80, 
CD86 on the DC and their interaction with CD28 on the T-cell. In the absence of Signal 2, 
CD4+ T cells become anergic or die (95, 96). Delivery of Signals 1 and 2 enables T-cell 
expansion and is accompanied by effector cytokine release by the T-cells. Signal 3, or 
differentiation, is mediated by DC soluble or membrane-bound factors, mainly cytokines, 
which help commit and “polarize” the expanding CD4+ T cells into a particular T helper (Th) 
cell lineage. Studies also show that the duration of antigen presentation and the strength of the 
TCR signal might affect T-cell differentiation (97). The activation of naïve T cells is 
characterized by sequential events on the T-cells that include the upregulation of CD69, 
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CD25 and CD44 (98), the downregulation of CD62L (99) and finally, by the production of 
effector cytokines. 
 
Each Th cell lineage produces a distinct set of effector cytokines that are important in 
turn for host resistance against different types of microbes. Each lineage is also characterized 
by the expression of lineage-specific transcription factors (100). These aspects are also 
summarized in Figure 2 and discussed briefly. IL-12 production favors the differentiation of 
Th1 cells during priming (101). Th1 cells produce TNF-α and IFN-γ, and through these 
cytokines, especially IFN-γ, activate the anti-microbial response of macrophages (102). 
However, there are also reports of IL-12-independent Th1 differentiation and IFN-γ release 
(103). IL-4 and IL-13 on the other hand, promote the differentiation of Th2 cells. Th2 cells 
produce IL-4, IL-5 and IL-10 and mediate host resistance to helminths (102, 104) (102, 105, 
106). The combination of IL-23, IL-6 and TGF-β can promote the differentiation of Th17 
cells. This Th lineage produces IL-17 and IL-22, important in triggering neutrophil responses 
and host resistance to fungi. TGF-β is also involved in the differentiation of regulatory T 
cells. These T cells produce IL-10 and TGF-β, and are important in controlling inflammation 
and dampening immune responses (107, 108). DCs are certainly a major source of IL-12 and 
IL-23 but interestingly, not for IL-4 and IL-13. 
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Figure 2. Activation of CD4+ T cells into Th cell lineages. Signal 1 (antigen presentation), 
Signal 2 (co-stimulation) and Signal 3 (differentiation). Th cell lineages are characterized by 
expression of lineage-specific transcription factors and the production of distinct effector 
cytokines. Adapted from (108).  
 
1.7. Mycobacteria 
 
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium 
tuberculosis (Mtb). TB is one of the top ten causes of death in the world and remains 
therefore a major global health concern (109). Infection is transmitted by the inhalation of 
aerosols harboring Mtb. The live attenuated strain of M. bovis called Bacille Calmette-Guérin 
(BCG) is the only available vaccine against TB, which was approved by the World Health 
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Organization (WHO) in 1928. Although there is a lot of debate regarding the efficiency of 
BCG in adults, its role in controlling childhood TB is accepted (110). 
 
1.7.1. BCG, History and Immune response 
 
In 1905 Guerin first found that TB in cattle could be caused by a virulent bovine 
strain of the tubercle bacillus. In the process of developing BCG as a vaccine for TB, Guérin 
and Calmette repeatedly cultured the bacillus on different culture media to reduce its 
pathogenic nature. It was in 1921, after 230 passages, that Guérin and Calmette were 
confident about the safety of BCG (111). Although the WHO approved BCG as a vaccine 
against TB in 1928, the Lübeck disaster in 1930 led to its withdrawal from national 
vaccination campaigns, until the end of the Second World War, when BCG vaccination was 
again introduced in various countries (112). 
 
Understanding the immune response to BCG is a prerequisite for improving BCG on 
a rationale basis, be it to develop new BCG variants or to implement new vaccination 
strategies. In clinical practice, BCG is given intradermally in the skin (113), which requires 
highly skilled practitioners to correctly and reproducibly deliver it. The degree of protection 
conferred by BCG vaccination against Mtb challenge was tested in various animal models 
using different routes and doses of BCG (114). BCG triggers a Th1 response, an immune 
response capable of controlling mycobacterial infection (115). Production of Th1 cytokines 
IFN-γ and TNF-α, also correlates with protective immune responses against TB in humans 
and mice (116). Clinical studies confirm that BCG dose can influence the frequency and 
intensity of T cell responses (117). Although, TB is predominantly a lung disease, BCG-
mediated protection in the lungs can be initiated to a similar degree by either intranasal or 
subcutaneous routes of vaccination (118). This suggests that pulmonary protection can be 
generated even by vaccination in the skin. Indeed, a group of CXCR3+CCR6+CD4+ memory 
T cells are now considered as major players that champion, the recall response to Mtb 
epitopes during challenge (119). However, the importance of bi- and multifunctional CD4+ T 
cells that produce IFN-γ, TNF-α and IL-2 in immune protection against TB is less defined 
(120). 
 
In addition, a higher dose of BCG administrated intratracheally gives more protection 
than a lower dose, but the use of a higher dose could lead to an increase in adverse pathology 
in lung (118). Interestingly, BCG is also used to treat bladder cancer. The anti-tumor 
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properties of BCG is observed in both humans (121) and in animal models (122, 123). Heat-
killed BCG (HK-BCG) has been reported to trigger similar anti-tumor activity as live BCG in 
the immunotherapy of bladder cancer (124, 125), while live BCG has been argued to be 
better than HK-BCG in generating a protective immune response against Mtb (126).  
 
1.7.2. Recombinant BCG vaccines 
 
Although BCG is protective against childhood TB, its immune protection gradually 
wanes over time. New strategies are needed for preventing new TB cases. One strategy is to 
improve BCG vaccine efficacy by using recombinant BCG (rBCG) strains that provide better 
protection and safety than the parent BCG vaccine. Towards this aim mycobacterial antigens 
have been introduced and overexpressed in BCG. The immunogenicity and protection of such 
BCG constructs have been tested in mice. Immunization with rBCG, co-expressing the fusion 
protein Ag85B-ESAT6-Rv3620c lead to a significant increase in the production of Th1 
cytokines IFN-γ, TNF-α and IL-2 (127). Studies were BCG was made to overexpress Ag85A, 
Ag85B and ESAT-6 generally reveal improved recall responses to the antigens overexpressed 
but protection against Mtb challenge is either lacking or partial (128-130). Together, it 
suggests that overexpression of Mtb antigens in BCG is not enough to improve BCG vaccine 
efficacy. This also raises concerns about the choice of antigens used in these constructs or the 
strategy itself.  
 
On the other hand, an rBCG created with the aim of modulating phagocytic cell 
function has yielded more promising results. This rBCG is an urease C (ureC)-depleted BCG 
that expresses listeriolysin (hly) from Listeria monocytogenes (BCG ΔureC::hly Hm) is 
constructed to improve phagosome acidification in infected APCs that in turn assist BCG 
antigen release and antigen loading onto MHC (131). Pre-clinical studies have shown that 
mice vaccinated with BCG ΔureC::hly Hm, but not the parental BCG, were better protected 
against Mtb (132). A phase I clinical trial with this rBCG has improved IFN-γ-producing T-
cell responses in BCG-naïve and BCG-immunized individuals compared to parental BCG 
(131). 
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2. METHOD DEVELOPMENT 
 
To investigate DC migration to DLN and T-cell priming to BCG, requires appropriate 
functional assays. Methodologies used in this thesis include but not limited to the assays 
summarized below. For a more detailed description of these and other methods, the reader is 
referred to the materials and methods of each respective study. 
 
2.1. Migration assays 
 
2.1.1. CFSE – Migration assay: (Paper I – IV) 
 
This assay was developed to identify and quantify the cells migrating from the 
footpad to the DLN in response to BCG, figure 3. To track migrating cells we injected BCG 
in the hind footpad of mice and 24hrs before sacrifice, CFSE was injected in same footpad 
that previously received BCG. Flow cytometry was used to characterize CFSE-labeled cells 
in the DLN, the popliteal LN. In certain experiments, confocal microscopy was used to 
investigate the distribution of CFSE-labeled cells in the DLN. Unlike FITC skin painting that 
measures cumulative cell migration from skin to DLN in response to topical application of 
contact sensitizers, the CFSE migration assay enables the identification of cells migrating 
from skin to DLN within a defined, 24hr period, in response to an injected stimulus, in our 
case BCG. The assay is discussed in more detail in the discussion section of this thesis and in 
paper IV.  
 
 
Figure 3. CFSE – Migration assay showing footpad injection with BCG followed by CFSE 
injection into same footpad, which previously got BCG. Analysis of DLN for immune cells 
through flow cytometry and microscopy. 
Hind Footpad C57BL/6 mice 
BCG 
Flow cytometry/ Microscopy  
  
DLN 
CFSE 
24hrs 
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2.1.2. Adoptive transfers: (Paper I, II & IV) 
 
Numerous studies on adoptive transfer strategies have been useful in addressing not 
only migration of DCs but also the activation and expansion of antigen-specific T cells in 
vivo. Adoptive transfer experiments with DCs were performed to study the contribution of 
DC-extrinsic and -intrinsic factors in the relocation of DCs to the DLN after BCG infection. 
The above is achieved by labeling BMDCs with CFSE in vitro and investigating the 
frequency of CFSE-labeled BMDCs in DLN by flow cytometry figure 4 (paper I and IV). On 
the other hand, adoptive transfer experiments with mycobacteria Ag85B-specific P25 TCRTg 
T cells allowed us to investigate activation markers, proliferation and cytokine production by 
BCG-antigen specific CD4+ T cells in vivo, also by flow cytometry.   
  
 
 
 
Figure 4. Adoptive transfer includes (A) footpad injection of CFSE-labeled BMDCs into 
C57BL/6 Followed by BCG injection in the footpad and analyzing the immune cells by flow 
cytometry. (B) intravenous (I.V) injection of CFSE-labeled P25 TCRTg cells into the tail 
vein of C57BL/6. Followed by BCG injection in the footpad and analyzing the immune cells 
by flow cytometry.  
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C57BL/6 /Transgenic mice 
CFSE+ BMDC  
Flow  
cytometry 
  
DLN 
 P25 TCRTg  
cells			 
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2.2. DC- T cell co-culture assay: (Paper II) 
 
In vitro co-culture assays were performed with splenic DCs and naïve P25 TCRTg 
cells to investigate the impact of H. polygyrus on the priming of BCG-specific CD4+ cells. 
DCs were conditioned with either excretory–secretory product (HES) or soluble worm Ag 
(SWAg) from H. polygyrus for 2hrs and subsequently co-cultured with P25 TCRTg cells at a 
ratio of 1:5 (DC: T-cell) followed by BCG infection at a multiplicity of infection of 1. IFN-γ 
was measured in culture supernatants after 5 days. This assay allows one to investigate the 
effect of soluble molecules from H. polygyrys on BCG-triggered production of IFN- γ from T 
cells, which is otherwise difficult to address in vivo. 
 
2.3. Delayed type hypersensitivity (DTH): (Paper II) 
 
A DTH response to mycobacteria can be studied in mice by measuring the swelling of 
the mouse footpad after injection of purified protein derivative from Mtb (PPD). This is 
similar to the tuberculin skin test in humans used to assess BCG vaccination or TB infection 
status (133, 134). In our studies, mice were injected with BCG in the hind footpad, and 2 
weeks later the other footpad was injected with PPD. The magnitude of DTH was estimated 
in the PPD-injected footpad by recording the swelling over a period of 72hrs. This assay was 
adapted to investigate the effect of worm antigens on PPD-triggered DTH response in vivo. 
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3. DISCUSSION OF OBTAINED RESULTS 
 
Initiating the immune response in the LN is a complex process. It requires many steps 
and cellular interactions. An important step in this process is the transport of microbial 
components from the site of infection to the DLN. DCs play a major role in the transport of 
antigen from body surfaces such as skin (1), and are the most potent APC for activating näive 
T cells. In this part of the thesis our model and several of the main findings obtained in our 
model are discussed. The reader is referred to each paper for a more detailed description of 
experiments. 
 
This thesis focuses on DC migration and its consequences for CD4+ T-cell priming to 
BCG. CFSE, a fluorescent cell-staining dye, was used to label skin cells in situ and to track 
their migration from footpad to DLN over a period of 24hrs (paper I-IV). Clinically, BCG is 
given intradermally as a vaccine against tuberculosis, but to inject into the dermis requires 
skill and training (135). Therefore, these injections may not always be given truly 
intradermal, but a combination of intradermal and subcutaneous. The same likely happens 
during a footpad injection. In any case, there are several advantages of injecting BCG in the 
footpad. First, the immune response is concentrated in the pLN, the primary, DLN (paper I). 
This makes it easier to study the immune response. On the contrary, there are 2 to 3 auricular 
LNs in mice and these are not always consistently present (136). Second, one can inject larger 
volumes in the footpad (10-50 µl) compared to the ear (5-10 µl), which makes the footpad a 
more flexible site. 
 
In our CFSE-based assay, MHC-IIhigh CD11c+/low skin DCs are a major population 
migrating in response to BCG. Nevertheless the CFSE+ skin DCs in both infected and control 
animals in our model had increased expression of co-stimulatory molecules, CD80 and CD86 
(paper I) suggesting that migrating skin DCs are activated irrespective of the stimulation, 
consistent with a previous report (137). Interestingly, there is a reduction in BCG-triggered 
skin DC migration in mice infected with H. polygyrus (paper II). This suggests that an 
intestinal nematode infection in the intestine can alter BCG-triggered migration of DCs from 
skin to DLN. In contrast to our findings, neutrophils rather than DCs were found to be a 
major population relocating to DLN in response to BCG infection in the ear dermis (138). 
This disparity could be due to the different routes of inoculation (138). The mouse ear might 
be more prone to neutrophil responses compared to other cutaneous sites such as the footpad. 
Indeed, neutrophils are rapidly recruited to the mouse ear after intradermal Leishmania major 
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infection or the simple inoculation of a needle to the ear (139). Inoculation of Toxoplasma 
gondii in the ear also triggers rapid neutrophil swarming in ear DLNs (140). In the study by 
Abadie et al, the authors did not find co-localization between CD207+ cells in the skin with 
BCG (138). They interpreted this as an absent role for migratory DCs in transporting bacilli 
to the DLN. Since EpCAM (CD326) and langerin (CD207) stain similar DC subsets, and 
since we found EpCAMlow CD11bhigh skin DCs to be a major cell population relocating to 
DLN in response to BCG, it is possible that the authors simply missed this population in their 
study. In line with our findings, a study with Kaede-transgenic mice that express a photo-
convertible fluorescence protein also found that CD11c+ DCs moved to DLN in response to 
BCG (141).  
 
DC migration towards LN is considered an important step in initiating the immune 
response (1). In line, failure in DC migration leads to poor induction of immunity (142). 
Lymph-derived DCs are important in maintaining the HEVs and lymphocyte recruitment 
through lymph in LN (143, 144). BCG arrival to the DLN was a prerequisite for priming 
mycobacteria-specific P25 TCRTg cells. This is supported by other studies showing that live 
bacilli in the DLN are needed for the initiation of T-cell responses to mycobacteria (145, 
146). It is unclear from our experiments if migratory skin DCs initiate the immune response 
to BCG by directly presenting antigen to T-cells or indirectly by transferring the antigen to 
LN-resident DCs. Antigen transfer from migratory skin DCs to LN-resident DCs has been 
reported for the priming of CD8+ T-cells to Herpes simplex virus (HSV) infection in the skin 
(147). Studies with Mtb suggest that antigen transfer occurs from adoptively transferred, 
BMDCs to LN-resident DCs in the lung-draining mediastinal LN, and that this optimizes 
CD4+ T-cell priming to Mtb (148). 
 
The number of antigen-bearing DCs that reach the DLN is associated with the 
magnitude and quality of CD4+ T-cell priming (149), suggesting an important role for 
migratory DCs in modeling adaptive immune responses. In line with this, blockade of skin 
DC migration in our model by injection of pertussis toxin (PTx) in the footpad completely 
ablates proliferation of P25 TCRTg cells and reduces mycobacterial load in the DLN (paper 
I). Similarly, CCR7-deficient mice, which lack skin-derived DCs and LCs in skin DLN, have 
impaired T-cell responses to antigens inoculated in the skin (16). 
 
Further, we found that gut infection with the nematode H. polygyrus had a negative 
impact on CD4+ T-cell priming to BCG (paper II). As discussed before, H. polygyrus reduced 
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BCG-triggered skin DCs migration to DLN. These results may explain in part reduced BCG 
vaccine efficacy and increase susceptibility to mycobacterial infection in individuals carrying 
worms in their gastrointestinal tract (150). Others have shown that there is an increase in 
concentration of TGF-β, a regulatory cytokine, in the cerebrospinal fluid and in the serum of 
H. polygyrus-infected mice (151). This increase in TGF-β secretion has been found to be 
important for establishment of the worm infection by regulating host immune response (152). 
TGF-β has been implicated in worm-mediated inhibition of several inflammatory diseases 
(153). It has also been reported that chronic infection with intestinal worms reduce immunity 
to BCG vaccination in humans and that chronical intestinal worms are associated with 
increased production of TGF-β by peripheral blood mononuclear cells (PBMC) (154). H. 
polygyrus and its HES are believed to regulate TGF-βR signaling. Interestingly, TGF-β can 
drive DCs towards a more regulatory phenotype (155-157). However, from in vitro cultures 
we found that HES acts directly on T cells rather than on DCs. Since HES is a complex 
mixture of molecules (158), more work is needed to investigate its inhibitory effects on cells 
of the immune system. 
 
Several DC subsets have been reported in mucosa, skin and SLOs (15). By employing 
previously established markers for identifying subsets of migratory skin DCs (17, 159, 160) 
we were able to characterize skin DC subsets in our model and identify EpCAMlow CD11bhigh 
DCs as the main migratory skin DC subset to relocate to DLN in response to BCG (paper I). 
Indeed, there is an emerging role for migratory EpCAMlow CD11bhigh DCs during infection. 
This subset has been reported to expand in skin DLN after intradermal infection with BCG or 
E. coli (160) and to promote priming of CD8+ T cells to an adenoviral vector delivered via 
microneedle arrays (161). Another report shows that this subset engulfs L. major parasites in 
the skin (162).  
 
We investigated the molecules that favor the migration of skin DCs to DLN after 
BCG infection. BCG-triggered skin DC migration is dependent on IL-1R and MyD88 
signaling (paper I). MyD88 is an important molecule in mycobacterial-induced DC activation 
and host resistance to Mtb (163). MyD88 is important for both IL-1R and IL-18R signaling 
but it also signals downstream of several TLRs (27). The phenotype of MyD88-/- and IL-1R-/- 
mice infected with Mtb clearly suggests that MyD88 signaling downstream of IL-1R 
signaling is more important than TLR signaling (164). Both DC adoptive transfer and bone-
marrow radiation chimera experiments support the requirement for MyD88 in DC migration 
(paper I). We studied several gene-deficient mice in our CFSE-based migration assay. 
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Interestingly, we did not find a phenotype for IL-1α-/-, IL-1β-/-/IL-18-/- or Caspase-1-/- mice 
(paper IV). There may still be IL-1β release in Caspase-1-/-mice, as there is evidence for 
Caspase-1-independent IL-1β production in M. tuberculosis-infected mice (164). Further, 
comparison of IL-1α-/-, IL-1β-/- and IL-1α-/-/IL-1β-/- mice during M. tuberculosis infection 
reveals a compensatory role for these cytokines in host resistance (164, 165). We speculate 
that the observed redundancy of IL-1α and IL-1β in BCG-triggered skin DC migration is 
indicative of a similar mechanism as that above. Performing the CFSE migration assay with 
IL-1α-/-/IL-1β-/- mice will help clarify this.  
 
The fact that MyD88-/- mice only have a partial phenotype in our model suggests that 
there must be additional pathways involved in DC influx and BCG entry into DLN. One 
possible candidate is the cytosolic adaptor molecule Caspase recruitment domain family 
member 9 (CARD9). CARD9-/- mice fail to mount protective inflammatory responses due to 
defective production of pro-inflammatory cytokines by myeloid cells (166). This adaptor 
molecule is important for C-type lectin receptor signaling (167) and regulates production of 
IL-1β , TNF-α  and IL-12p40 during M. tuberculosis infection (168). 
 
Inflammation promotes the egress of DCs from tissue. Pro-inflammatory cytokines 
are produced in response to microbes, contact sensitizers or TLR ligands and are believed to 
influence the egress of DCs from tissue to DLN (169). Similarly, the production of pro-
inflammatory cytokines at the BCG injection site may promote the egress of skin DCs to 
DLN. In line, we detected mRNA accumulation of IL-1α, IL-1β and TNF-α early after BCG 
injection in the skin (Paper IV). Studies show that pre-conditioning an injection site in the 
skin can regulate DC migration to DLN. In particular, administration of TNF-α and IL-1α/β 
was found to trigger skin DCs migration in other models (81, 170). The above-mentioned 
approach to improve DC migration was adopted in our model. Injecting the footpad of IL-1R-
I-/- mice with IL-12p40 homodimer but not TNF-α restored BCG-triggered skin DC 
migration. Pre-conditioning the footpad with TGF-β or HES significantly reduced BCG-
triggered skin DCs migration to DLN. The latter suggests that TGF-β and HES can impair 
DC function (155). 
 
BCG dose has also been suggested to be important against M. tuberculosis challenge 
when different routes of BCG vaccinated were compared (114). When we investigated the 
importance of dose in skin DC migration to DLN, we found that using 10 times less BCG 
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than our standard dose lead to a reduction in skin DC migration (paper IV). In line, clinical 
studies suggest that the frequency and intensity of T-cell responses to BCG may be dose-
dependent (117). 
 
While historical studies have suggested that the attenuated H37Ra strain of Mtb elicits 
better survival in mice compared with heat-killed H37Ra after challenge with virulent of Mtb 
(126), the mechanisms are not fully understood. The above does not seem to be due to 
improved DC migration to DLN, since HK-BCG triggers similar relocation of skin DC to 
DLN as live BCG (paper IV). The originally believed, enhanced effects of live mycobacterial 
preparations over inactivated mycobacteria may have been overestimated. Indeed, whole-cell 
lysate preparations of Mycobacterium species are currently in the pipeline of TB vaccine 
development, examples being DAR-901, M. vaccae and RUTI (171-173). 
 
HK-BCG has been reported to have similar anti-tumor activity as live BCG in the 
immunotherapy of bladder cancer (124, 125). Interestingly, inoculation of HK-BCG in the 
footpad skin induces a stronger expansion of P25 TCRTg cells in the DLN compared to live 
BCG. This is at least true during the peak of the response to live BCG. Time-course 
experiments need to be performed to provide additional information on the difference 
between these inoculations. It has been recently shown that EsxH from the Mtb type VII 
secretion system inhibits antigen processing in macrophages and DCs (174). The inability of 
HK-BCG to secrete inhibitory effector molecules could explain why it is better than live 
BCG in triggering T-cell expansion in vivo. It is also possible that soluble mycobacterial 
products (more abundant in a HK-BCG preparation) gain direct access to lymphatics after 
being injected in the footpad and as such become readily available to LN-resident DCs in the 
DLN. This remains to be investigated. 
 
In summary, this thesis reports the discovery of a migratory skin DC sub-population 
that relocates to DLN in response to BCG. This population relocates together with bacilli in 
an IL-1R-MyD88-dependent manner. A redundancy exists between IL-1α and IL-1β is this 
process. Further, a chronic intestinal nematode infection impairs BCG-triggered responses 
including skin DC migration to DLN. Skin DC migration is BCG-dose dependent and does 
not require viable bacilli. These findings on the early sequence of events that lead to T-cell 
priming in the DLN may be relevant in vaccine development against TB and in DC-based 
immunotherapy. 
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4. CONCLUSION & FUTURE PERSPECTIVES 
 
We found EpCAMlow CD11bhigh cells to be the main skin DC sub-population that 
migrates to DLN in response to BCG injection in the skin (paper I). This is also in part 
supported by data from paper II. In line with our findings, other reports suggest that a similar 
population migrates from skin to DLN after E. coli, BCG (160), chemical stress or 
mechanical injury (20). Our observations also indicate the importance of these migrating DCs 
in transporting live BCG to the DLN to trigger CD4+ T-cell priming (paper I). This however 
does not establish EpCAMlow CD11bhigh DCs as DCs that champion the priming CD4+ T cells 
to BCG or other mycobacteria for that matter. This could be addressed in different ways. 
 
The antigen-presentation capacity of this as well as other DC subsets from skin DLN 
could be investigated with naïve P25 TCRTg cells in antigen-presentation assays, similar to 
those previously performed with gB-I TCRTg cells and HSV-1-infected LN DCs (175). 
Another approach would be to perform adoptive transfer experiments of BCG-pulsed DCs 
into MHC-II-/- mice previously injected with naïve P25 TCRTg cells. The transfer into MHC-
II-/- recipients would control for antigen-leakage. This approach would allow one to study the 
ability of different DC subsets in priming T cells in vivo, but is potentially limited by the DC 
numbers needed to perform these experiments. A third way forward could be to study the 
priming of P25 TCRTg cells in mice where DC subsets are absent or can be depleted in vivo, 
as recently studied during infection with Candida albicans (176). Recent advances in single-
cell whole transcriptome analysis (177-179) would however allow profiling of both sparse 
and heterogeneous skin DC subsets. Such analyses could be attempted both from DCs 
isolated from BCG-stimulated LNs in vivo, or from in vitro-activated subsets. 
 
Another highlight of this thesis is that skin DC migration and BCG entry into DLN is 
regulated by IL-1R-MyD88 signaling (paper I). Interestingly, the ligands for IL-1R, IL-1α 
and IL-1β, were found to be redundant in this relocation of cells and bacilli to DLN (paper 
IV). Also, the requirement for IL-1R and MyD88 seem to be partial. This is interesting since 
IL-1R and MyD88 are known to be important regulators of DCs and inflammation. 
Additional pathways or other, yet unknown, compensatory mechanisms may be happening in 
our model. This is not easy to investigate. One possibility is to screen gene-targeted mice in 
the CFSE-based migration assay. Also interestingly, injection of the footpad with PTx prior 
to BCG injection reveals a requirement for migratory skin DCs in T-cell priming. This 
treatment totally blocked DC migration and inhibited expansion of naïve P25 TCRTg cells in 
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the DLN. However, PTx treatment did not ablate mycobacterial entry into DLN, suggesting 
that some mycobacteria seem to access lymphatic vessels and reach the DLN in the absence 
of DC (or other cellular) transport, One way to investigate the contribution of such lymph-
borne, “cell-free” relocation of BCG to DLN is by injecting BCG directly into lymphatic 
vessels and studying the outcome of this inoculation route on the priming of P25 TCRTg 
cells. 
 
Another interesting observation was that HK-BCG seems to be superior to live BCG 
at priming P25 TCRTg cells in the DLN. This is somewhat contradictory to the belief that 
live BCG is better than killed BCG at generating protective immune responses to Mtb (126). 
However, several lysate/heat-inactivated-based mycobacterial preparations are currently 
being tested against TB (109) The outcome of immunization with live versus killed 
mycobacteria merits further investigation. We speculate that after injection of HK-BCG, P25 
TCRTg cells are primed mainly by LN-resident DCs that gain quicker access to free antigen 
through lymphatics, possibly involving also the LN conduit system (21). This could be 
studied as previously mentioned in the Results and Discussion section, in experiments using 
PTx or CCR7-/- mice.  
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